A PIK3CA-mutant breast cancer metastatic patient-derived organoid approach to evaluate alpelisib treatment for multiple secondary lesions-Reference-Cited by-同舟云学术

A PIK3CA-mutant breast cancer metastatic patient-derived organoid approach to evaluate alpelisib treatment for multiple secondary lesions

Published:2022-07-22 Issue:1 Volume:21 Page:
ISSN:1476-4598
Container-title:Molecular Cancer
language:en
Short-container-title:Mol Cancer

Author:

Donzelli Sara,Cioce Mario,Sacconi Andrea,Zanconato Francesca,Daralioti Theodora,Goeman Frauke,Orlandi Giulia,Di Martino Simona,Fazio Vito Michele,Alessandrini Gabriele,Telera Stefano,Carosi Mariantonia,Ciliberto Gennaro,Botti Claudio,Strano Sabrina,Piccolo Stefano,Blandino Giovanni

Funder

Fondazione AIRC under 5 per mille

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology,Molecular Medicine

Link

https://link.springer.com/content/pdf/10.1186/s12943-022-01617-6.pdf

Reference15 articles.

1. Gennari A, Andre F, Barrios CH, Cortes J, de Azambuja E, DeMichele A, Dent R, Fenlon D, Gligorov J, Hurvitz SA, et al. ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer. Ann Oncol. 2021;32:1475–95.

2. Razavi P, Chang MT, Xu G, Bandlamudi C, Ross DS, Vasan N, Cai Y, Bielski CM, Donoghue MTA, Jonsson P, et al. The genomic landscape of endocrine-resistant advanced breast cancers. Cancer Cell. 2018;34:427-438.e426.

3. Bertucci F, Ng CKY, Patsouris A, Droin N, Piscuoglio S, Carbuccia N, Soria JC, Dien AT, Adnani Y, Kamal M, et al. Genomic characterization of metastatic breast cancers. Nature. 2019;569:560–4.